DGAP-Adhoc Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

Nachrichtenquelle: EQS Group AG
29.10.2020, 14:04  |  123   |   |   

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

29-Oct-2020 / 14:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
Jena, October 29, 2020

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,335.5 million in fiscal year 2019/20 (previous year EUR 1,459.3 million) and has thereby exceeded the forecast of approx. EUR 1.3 billion provided on July 15, 2020. This corresponds to a decline of -8.5% vs. the past year. After adjustment for currency effects[1], the decline amounted to -8.7%. In the fourth quarter of 2019/20, revenue reached EUR 367.6 million (Q4 2018/19: EUR 431.7 million), a decline of -14.9%. After adjustment for currency effects, the decline amounted to around -14.5%.

Earnings before interest and taxes (EBIT)[2] amounted to EUR 177.6 million in fiscal year 2019/20 (previous year EUR 264.7 million). EBIT margin (EBIT / revenue) was 13.3% (previous year 18.1%). In the fourth quarter of 2019/20, EBIT amounted to EUR 65.7 million (Q4 2018/19: 80.5 million), EBIT margin was 17.9% (Q4 2018/19: 18.6%).

Earnings per share (EPS)[3] declined to EUR 1.37 (previous year EUR 1.79). In the fourth quarter of 2019/20, EPS was EUR 0.60 (Q4 2018/19: EUR 0.57).

Full results for fiscal year 2019/20 will be provided on Dec 11, 2020.

Carl Zeiss Meditec broadly expects a recovery of its markets in fiscal year 2020/21 and thereby a return to growth in revenue and EBIT. Due to the current trend in COVID-19 infections in Europe and North America, an additional impact from the pandemic cannot be ruled out at the outset of the new fiscal year, though. From today's point of view, the company expects revenue and EBIT for the first months of the new fiscal year 2020/21 to come in below last year's values for the same period.
 

 

Seite 1 von 2
Carl Zeiss Meditec Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic 29-Oct-2020 / 14:04 CET/CEST …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel